Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients

Isabelle Magalhaes,1,2 Karine Pingris,1,2 Christine Poitou,4,5,6 Stéphanie Bessoles,7 Nicolas Venteclef,4,5 Badr Klaaf,1,2,3 Lucie Beaudoin,1,2 Jennifer Da Silva,1,2,3 Omran Allatif,4,5,6 Jamie Rossjohn,8,9 Lars Kjer-Nielsen,10 James McCluskey,10 Séverine Ledoux,1,2,3,11 Laurent Genser,4,5,6 Adriana Torcivia,12 Claire Soudais,7 Olivier Lantz,7 Christian Boitard,1,2,3,13 Judith Aron-Wisnesky,4,5,6 Etienne Larger,1,2,3,13 Karine Clément,4,5,6 and Agnès Lehuen1,2,3,13

1INSERM U1016, Institut Cochin, Paris, France. 2CNRS, UMR8104, Paris, France. Laboratoire d’Excellence INFLAMX, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Sorbonne Universités, Université Pierre et Marie Curie, Paris, France. 4INSERM U1016, Institut de Cardiometabolisme et Nutrition (ICAN), Paris, France. 5ICAN, Nutrition Department, Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital de la Pitié–Salpêtrière, Paris, France. 6INSERM U932, Institut Cochin, Paris, France. 7ARC, Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia. 8Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom. 9Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia. 10Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia. 11AP-HP, Service des Explorations Fonctionnelles, Centre de référence de prise en charge de l’obésité, Louis Mourier Hospital, Paris, France. 12AP-HP, Département de Diabétologie, Cochin Hospital, Paris, France. 13AP-HP, Département de Diabétologie, Cochin Hospital, Paris, France.

Obesity and type 2 diabetes (T2D) are associated with low-grade inflammation, activation of immune cells, and alterations of the gut microbiota. Mucosal-associated invariant T (MAIT) cells, which are innate-like T cells that recognize bacterial ligands, are present in blood and enriched in mucosal and inflamed tissues. Here, we analyzed MAIT cells in the blood and adipose tissues of patients with T2D and/or severe obesity. We determined that circulating MAIT cell frequency was dramatically decreased in both patient groups, and this population was even undetectable in some obese patients. Moreover, in both patient groups, circulating MAIT cells displayed an activated phenotype that was associated with elevated Th1 and Th17 cytokine production. In obese patients, MAIT cells were more abundant in adipose tissue than in the blood and exhibited a striking IL-17 profile. Bariatric surgery in obese patients not only improved their metabolic parameters but also increased circulating MAIT cell frequency at 3 months after surgery. Similarly, cytokine production by blood MAIT cells was strongly decreased after surgery. This study reveals profound MAIT cell abnormalities in patients harboring metabolic disorders, suggesting their potential role in these pathologies.

Introduction

Obesity is associated with low-grade inflammation in adipose tissue (AT) and dysfunctional adipocytes producing inflammatory molecules. The accumulation in AT of immune cells such as macrophages, lymphocytes, neutrophils, and mast cells is thought to participate in obesity and obesity-induced type 2 diabetes (T2D). In contrast, innate immune semi-invariant natural killer T (iNKT) cells are enriched in AT of lean subjects compared with AT of obese patients (1). Indeed, iNKT in AT may exert immunoregulatory functions and influence insulin resistance in murine models (2, 3). Mucosal-associated invariant T (MAIT) cells are a novel subset of innate-like immune cells found in peripheral blood, intestinal mucosa, and abundantly in human liver (4–6). Like iNKT cells, MAIT cells express an invariant T cell receptor α chain, the Vα7.2-Jα33 chain in humans. MAIT cells can produce IFN-γ, granzyme B (GrB), and IL-17 (4); are restricted by the major histocompatibility complex class I–related molecule MR1 (7); and are activated by cells infected by different microorganisms (8). Vitamin B2 (riboflavin) metabolites produced by bacteria and yeasts are required to generate MAIT cell–activating ligands (9–12). It has been recently shown that host-derived small molecules, such as methylglyoxal and glyoxal, form with the bacterial riboflavin metabolite 5-A-RU, a potent MAIT cell ligand (13). Interestingly, methylglyoxal levels are increased in diabetic patients (14).

The absence of MAIT cells in the intestinal lamina propria of germ-free mice (7) underlies the role of the gut commensal flora in MAIT cell expansion and/or survival in the periphery. The composition of the gut microbiota is altered in obesity (15, 16) and diabetes (17, 18), impacting the riboflavin pathway, among others. Two conditions that result in weight loss and improved metabolic status, i.e., diet (16) and gastric bypass (19–21), induce a shift of the gut microbiota.

Given the homing capacity of MAIT cells to the gut and their activation by bacterial products, one can speculate that changes in gut microbiota would in turn influence the MAIT cell compartment. Here, we analyzed MAIT cell frequency and cytokine production in T2D patients and in severely or morbidly obese patients before and after weight loss induced by bariatric surgery.

Results

Blood MAIT cell frequency is decreased in T2D and obesity. MAIT cells are characterized by the high expression of CD161; thus, we identified MAIT cells as CD3+CD4+CD161+Vα7.2+ lymphocytes. The development of MRI-6-HM tetramers specifically detecting
MAIT cells (11) allowed us to confirm that CD3<sup>+</sup>CD4<sup>−</sup>CD161<sup>hi</sup>V<sup>α</sup>7.2<sup>+</sup> cells identified all MAIT cells in healthy individuals and obese patients. Ten individuals with high and low frequencies of MAIT cells were analyzed with MR1-6-HM tetramers (with the MR1-6-FP tetramer used as negative control). With the use of peripheral blood mononuclear cells (PBMCs) that were costained with MR1-6-HM tetramers and anti-V<sup>α</sup>7.2 antibodies, our results showed that MR1-6-HM tetramers identified all CD3<sup>+</sup>CD161<sup>hi</sup>V<sup>α</sup>7.2<sup>+</sup> cells (Figure 1A). Conversely, all CD3<sup>+</sup>CD4<sup>−</sup>CD161<sup>hi</sup>V<sup>α</sup>7.2<sup>+</sup> cells were stained by MR1-6-HM tetramers (data not shown). The majority of MAIT cells were either CD8<sup>+</sup> or double negative (Figure 1A). We then analyzed MAIT cell frequency in two cohorts of patients: T2D subjects, some of whom were obese (BMI ≥30 kg/m<sup>2</sup>, T2D group); and patients with severe obesity (BMI ≥35 kg/m<sup>2</sup>), candidates for bariatric surgery. These severely obese subjects included some patients with associated T2D. Healthy individuals were also part of the study. Table 1 summarizes clinical characteristics in the three groups. The range of circulating MAIT cell frequency in the healthy controls ranged from 0.2% to 7.6% of CD3<sup>+</sup> cells, with a median frequency of 1.82% (Figure 1B), comparable to previous reports (22–25). Compared with controls, the frequency of circulating MAIT cells in patients was significantly lower. It was even below the detection limit (0.001% of CD3<sup>+</sup> cells) in 12 of 69 (17%) subjects with severe obesity. In patients with detectable MAIT cells, the median MAIT cell frequency was 0.27% in nonobese T2D, 0.10% in obese T2D, and 0.04% in obese non-T2D subjects (<i>P</i> < 0.0001 compared with controls, Figure 1B). Interestingly, the frequency of circulating MAIT cells was negatively associated with subjects’ BMI (<i>ρ</i> = –0.55, <i>P</i> < 0.0001, Figure 1C) and, in severely obese patients, positively associated with serum levels of adiponectin, an insulin-sensitizing adipokine (<i>n</i> = 57, <i>ρ</i> = 0.29, <i>P</i> < 0.05, data not shown).

Since the decreased circulating MAIT cell frequency may result from activation-induced cell death, we analyzed the expression of activation markers in the T2D group. The expression of CD25 was upregulated in obese T2D patients as compared with healthy controls (median of 4.2% versus 1.3%, <i>P</i> < 0.0003) (Figure 1D). Of note, there was also a trend toward increased expression of CD69 in T2D patients as compared with controls (median of...
Fat mass (kg) | 58.4 ± 1.4
Leptin (ng/ml) | 80.7 ± 6.2

Influence of AT on MAIT cell phenotype. In order to better understand the homeostasis of MAIT cells in AT, we analyzed the expression of several markers by MAIT cells after coculture of PBMCs of healthy donors with AT samples from obese patients. Interestingly, the presence of AT dampened the expression level of the survival molecule Bcl-2 in MAIT cell AT in 21 of 22 cocultures (Figure 6A). The comparison of Bcl-2 expression in MAIT cells from the blood and the AT of five obese patients showed a similar decrease in Bcl-2 in MAIT cells from AT (Figure 6B). These results indicate that in AT, MAIT cells might be more impaired in their survival and function.

In summary, we report that MAIT cells in AT of obese patients have a Th17-like profile and show impaired survival and function. These findings suggest a potential role of MAIT cells in the immune response to AT in obesity.
suscceptible to cell death. Interestingly, in the same obese patient samples, we also observed an increased frequency of proliferating MAIT cells (Ki-67 expression) in AT as compared with blood (Figure 6C). In AT MAIT cells, Bcl-2 MFI was lower in Ki-67 + as compared with Ki-67 − cells (Figure 6D). Together, these data showing that proliferation of MAIT cells increased and their expression of Bcl-2 decreased in, or in the presence of, AT suggest that chronic activation of the MAIT cell population takes place locally.

**Attenuation of MAIT cell abnormalities after weight loss induced by bariatric surgery.** We next analyzed MAIT cells in the peripheral blood of the obese patients who underwent bariatric surgery (up to 12 months after surgery), which as expected improved metabolic and hormonal parameters (Figure 7, A–D). In agreement with previous reports (19, 21), BMI, glycated hemoglobin (HbA1C), and serum leptin diminished after the surgery, whereas serum adiponectin increased. Concomitantly, at 3 months after surgery, the MAIT cell frequency had already increased as compared with the initial frequency (0.66% vs. 0.06%, \( P = 0.01 \), Figure 7E). Of note, before surgery MAIT cells were below detection in 12 of 69 of the patients, while these cells were detected in all subjects after surgery. Six months after surgery, MAIT cell frequency further increased, reaching 0.9% of CD3+ cells, and then remained at the same level at 12 months after surgery. However, MAIT cell frequency was still significantly lower in obese patients who underwent surgery (but remained obese) than the frequency detected in lean controls (\( P = 0.04 \)). The profile of MAIT cell cytokine production was also assessed at 3, 6, and 12 months after surgery (Figure 7F and Supplemental Figure 2). Three months after surgery, the frequency of...
The frequency of circulating MAIT cells is decreased in T2D patients and even more dramatically in severe obesity. This diminished frequency is associated with increased production of IL-17 by circulating MAIT cells, and this Th17 shift was exacerbated in AT from obese patients. Importantly, bariatric surgery restored circulating MAIT cell frequency and dampened their functional alteration. These data highlight the potential role of MAIT cells in these metabolic diseases.

Discussion
Recent advances in understanding the pathophysiology of obesity and related T2D have established the involvement of the immune system, and the present study reveals major MAIT cell alteration in T2D and obese patients. The frequency of circulating MAIT cells is decreased in T2D patients and even more dramatically in severe obesity. This diminished frequency is associated with increased production of IL-17 by circulating MAIT cells, and this Th17 shift was exacerbated in AT from obese patients. Importantly, bariatric surgery restored circulating MAIT cell frequency and dampened their functional alteration. These data highlight the potential role of MAIT cells in these metabolic diseases.

MAIT cells producing the cytokines IL-2, GrB, and IL-17 was much lower than previously described, and in 12 of 69 (17%) severely obese patients, it was below our detection limit (<0.001% of CD3+ cells).

The decrease in circulating MAIT cell frequency in T2D and obese patients was accompanied by an increase in their activation status as defined by CD25 and CD69 expression. Similar observations were reported for patients with inflammatory bowel diseases (29) and with HIV (24). Moreover, the loss of circulating MAIT cells in T2D and obese patients was also associated with high levels of IL-17 production by MAIT cells, as previously reported in inflammatory bowel diseases (29). Similarly, in patients who underwent allogeneic stem cell transplantation — and thus were prone to graft-versus-host disease resulting in an excessive inflammatory environment — CD161 hiCD8+ cells, most likely mainly MAIT cells, were less frequent and produced more IL-17 (31). In the present study, MAIT cells exhibited an inflammatory profile (particularly Th17) in both groups of patients, yet with differences. The pattern of MAIT cell activation could reflect a proinflammatory environment as well as modified hormonal and metabolic conditions. The fact that MAIT cell production of IL-2, GrB, and IL-17 was markedly increased in T2D patients suggests that, in T2D and severe obesity, the degree and/or mediators of inflammatory environments and possibly other metabolic mediators resulting in MAIT cell activation may differ.

The frequency of IL-17 production by MAIT cells was markedly elevated in AT as compared with the level measured in peripheral blood in severe obesity. Moreover, in AT of obese patients, there was a substantially increased frequency of MAIT cells producing IL-17 (OM: 26.9%, SC: 76.2%) as compared with conventional CD4+ T cells (OM: 0.6%, SC: 4.7%), CD8+ T cells (OM: 0.14%, SC: 0.69%), and double-negative T cells (OM: 1.9%, SC: 8.5%) (AT SC data not shown). While all T cell subsets analyzed (CD8+ MAIT cells producing the cytokines IL-2, GrB, and IL-17 was still higher than in healthy controls. However, at 6 months after surgery, the frequency of MAIT cells producing GrB was comparable in patients and control individuals and was even lower for IL-2 in patients than controls. In contrast, IL-17 production remained increased as compared with controls at 6 and 12 months after surgery (1.1% and 1.5%, respectively, vs. 0.7%). There was no difference between diabetic and nondiabetic obese patients.

The decreased frequency of circulating MAIT cells detected as Vα7.2+ and CD161 hi was confirmed with human MR1 tetramers. Moreover, we did not observe an increase in frequency of CD161–Vα7.2+ T cells, excluding the possibility that the decreased MAIT cell frequency was due to the downregulation of CD161 surface expression. Of note, a recent study in patients with HIV confirmed that CD161–Vα7.2+ T cells do not bind MR1 tetramers and are not MAIT cells (26). Decreased circulating MAIT cell frequency has been described in different diseases: hepatitis C, HIV, tuberculosis, inflammatory bowel diseases, and severe infections (23, 24, 27–30). However, the MAIT cell frequency observed in T2D and obese patients was much lower than previously described, and in 12 of 69 (17%) severely obese patients, it was below our detection limit (<0.001% of CD3+ cells).

The decrease in circulating MAIT cell frequency in T2D and obese patients was accompanied by an increase in their activation status as defined by CD25 and CD69 expression. Similar observations were reported for patients with inflammatory bowel diseases (29) and with HIV (24). Moreover, the loss of circulating MAIT cells in T2D and obese patients was also associated with high levels of IL-17 production by MAIT cells, as previously reported in inflammatory bowel diseases (29). Similarly, in patients who underwent allogeneic stem cell transplantation — and thus were prone to graft-versus-host disease resulting in an excessive inflammatory environment — CD161 hiCD8+ cells, most likely mainly MAIT cells, were less frequent and produced more IL-17 (31). In the present study, MAIT cells exhibited an inflammatory profile (particularly Th17) in both groups of patients, yet with differences. The pattern of MAIT cell activation could reflect a proinflammatory environment as well as modified hormonal and metabolic conditions. The fact that MAIT cell production of IL-2, GrB, and IL-17 was markedly increased in T2D patients suggests that, in T2D and severe obesity, the degree and/or mediators of inflammatory environments and possibly other metabolic mediators resulting in MAIT cell activation may differ.

The frequency of IL-17 production by MAIT cells was markedly elevated in AT as compared with the level measured in peripheral blood in severe obesity. Moreover, in AT of obese patients, there was a substantially increased frequency of MAIT cells producing IL-17 (OM: 26.9%, SC: 76.2%) as compared with conventional CD4+ T cells (OM: 0.6%, SC: 4.7%), CD8+ T cells (OM: 0.14%, SC: 0.69%), and double-negative T cells (OM: 1.9%, SC: 8.5%) (AT SC data not shown). While all T cell subsets analyzed (CD8+ MAIT cells producing the cytokines IL-2, GrB, and IL-17 was still higher than in healthy controls. However, at 6 months after surgery, the frequency of MAIT cells producing GrB was comparable in patients and control individuals and was even lower for IL-2 in patients than controls. In contrast, IL-17 production remained increased as compared with controls at 6 and 12 months after surgery (1.1% and 1.5%, respectively, vs. 0.7%). There was no difference between diabetic and nondiabetic obese patients.

The decreased frequency of circulating MAIT cells detected as Vα7.2+ and CD161 hi was confirmed with human MR1 tetramers. Moreover, we did not observe an increase in frequency of CD161–Vα7.2+ T cells, excluding the possibility that the decreased MAIT cell frequency was due to the downregulation of CD161 surface expression. Of note, a recent study in patients with HIV confirmed that CD161–Vα7.2+ T cells do not bind MR1 tetramers and are not MAIT cells (26). Decreased circulating MAIT cell frequency has been described in different diseases: hepatitis C, HIV, tuberculosis, inflammatory bowel diseases, and severe infections (23, 24, 27–30). However, the MAIT cell frequency observed in T2D and
cells, CD4+ cells, Tregs, and γδT cells) expressed a very high level of CD69 in AT (data not shown), MAIT cells seemed particularly activated toward an IL-17 profile as compared with other T cell subsets. IL-12 and IL-18 have been shown to activate MAIT cells in an MR1-independent manner (32), indicating that not only MAIT cell–specific ligands, but also inflammatory molecules can activate them. MAIT cells express high levels of IL-7R (CD127), and IL-7 can promote IL-17 production by MAIT cells and license MAIT cell activation in the liver (5). In OM AT from obese patients, IL-7 among other adipokines was oversecreted by stromal vascular cells, a heterogeneous population of stem, progenitor, and differentiated cells (33). In addition to cytokines, MAIT cells could be activated through their TCR by specific ligands generated in the presence of bacterial riboflavin metabolites and methylglyoxal.

**Figure 4. MAIT cells in the AT of obese patients.** (A and B) Flow cytometry analysis of MAIT cells detected in the OM and SC AT. (A) Representative dot plots. (B) MAIT cell frequency in the blood, OM, and SC AT of healthy donors (n = 23, 7, and 4, respectively) and obese patients (n = 69, 31, and 7, respectively). *P < 0.0001. (C) MAIT cell frequency in paired blood and OM AT from 13 obese patients. (D) CD25 MAIT cell expression in OM AT of control individuals and obese patients (n = 5 and 17, respectively). (E) Frequency of T cell subsets in blood from control individuals (n = 15) and obese patients (n = 20) and in OM AT from obese patients (n = 13). *P < 0.04, †P < 0.0001. Mann-Whitney U test.
Changes in the gut microbiota composition that occur in obesity and T2D may impact gut permeability and the presence of bacterial products in AT (34), and methylglyoxal might accumulate in AT, as described in obese rats (35). Whatever the mechanism leading to the high IL-17 production by MAIT cells, this proinflammatory cytokine could influence and participate in the local inflammation of AT. IL-17 can activate JNK, which in addition phosphorylates IRS1, inducing insulin resistance (36).

In obese patients, in contrast to the low frequency of circulating MAIT cells, in AT their frequency was 10-fold higher. There was a similar trend for iNKT cells. The decreased frequency of circulating MAIT cells could reflect their increased cell death and/or their recruitment to AT in obese patients, as previously suggested for other immune cells, such as conventional CD8+ T cells (37). The impaired activation capacity of circulating MAIT cells from T2D patients in the presence of specific ligands revealed an exhausted status, which could represent a transition toward cell death. This exhaustion associated with a decline in MAIT cells was previously observed in patients with chronic HIV infection (24). The level of CCR5 and CCR6 (data not shown), which are highly expressed by MAIT cells (28), was comparable in healthy controls and patient groups, suggesting that circulating MAIT cells in obese and T2D patients have intact tissue-homing capacities. Here, MAIT cell frequency in AT remained comparable in obese and lean subjects. This can imply either that MAIT cells in AT are protected from the mechanisms responsible for their depletion observed in the peripheral blood, or that MAIT cells are also activated in AT and, although they may die, they are continuously recruited, explaining in part the lower frequencies in peripheral blood. This latter hypothesis is supported by several in vitro and ex vivo observations. In cocultures, AT from obese patients promoted MAIT cell activation in the presence of ligand as shown by their CD25 and CD69 upregulation (Supplemental Figure 3), and there was a higher frequency of Ki-67+ MAIT cells from AT than from blood in five pairs of obese patient samples. In cocultures, AT from obese patients decreased MAIT cell Bcl-2 expression, and in obese patients Bcl-2 expression in MAIT cells was lower in AT than in the blood. Thus, the AT environment seems to influence in various ways the homeostasis of MAIT cells.

<table>
<thead>
<tr>
<th>Table 2. Characteristics of control individuals and patients whose AT biopsy samples were analyzed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
</tr>
<tr>
<td>n</td>
</tr>
<tr>
<td>Age (yr)</td>
</tr>
<tr>
<td>Sex, F/M</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
</tr>
</tbody>
</table>

Adipose tissue biopsy samples were obtained from OM depots during bariatric surgery (obese group) or elective surgery (controls). #Mean ± SEM.
Bariatric surgery–induced weight loss and associated amelioration of patients’ metabolic and inflammatory status was accompanied by a significant increase of blood MAIT cell frequency already found at 3 months after surgery. Interestingly, using a linear mixed model, we found a kinetic association between the change in MAIT cell abundance and circulating levels of adiponectin (P = 0.036) that increased after the surgical procedure. This might suggest a possible relationship between increased MAIT cells and an improved metabolic and inflammatory status, since adiponectin is also considered to be a hormone with anti-inflammatory properties. In contrast, the association with circulating leptin that drastically diminished after surgery-induced weight loss was negative (P = 0.008, data not shown). Bariatric surgery is accompanied by changes in proinflammatory cytokine levels and vitamin status, as well as in carbohydrate intake, which is drastically reduced at 3 months after gastric bypass surgery, returning progressively to pre-surgery levels after 6 months (38). It is then tempting to speculate that these changes after surgery may influence the MAIT cell compartment and may in part be responsible, directly or not, for the increased frequency of MAIT cells. Whether and which changes in food intake or nutrient and related modification of gut microbiota (21) might influence MAIT cell abundance is an open question.

Taken together, our data revealed for the first time to our knowledge that T2D and obesity have a major impact on circulating and AT MAIT cell frequency and function: circulating MAIT cell frequency was profoundly decreased, and they produced more cytokines, such as IL-2, GrB, and IL-17, with exacerbated IL-17 production in AT. After bariatric surgery, MAIT cell abnormalities were markedly attenuated. The impact of the gut microbiota and the inflammatory environment on MAIT cells in patients with T2D and obese patients needs to be further explored. This article paves the way for deeper investigation of the mechanisms responsible for the prolonged Th17 shift of MAIT cells observed after bariatric surgery and whether gut microbiota, MAIT cell–specific ligands, MR1 tissue expression, and inflammatory mediators play a role.

**Methods**

**Healthy controls and patients.** Blood samples were collected from control individuals who did not report T1D or T2D and who were nonobese, i.e., had a BMI <30 kg/m². Patients from the T2D group were T2D outpatients consulting at the Hôtel-Dieu hospital in Paris with no acute event. Their mean HbA1C was 8.1%. Most received metformin (73%), and 43% also received insulin. The severe obesity cohort consisted of 69 subjects involved in a bariatric surgery program at the ICAN at Pitié-Salpêtrière hospital in Paris. Thirty-nine patients were examined at 3, 6, and 12 months after bariatric surgery. These subjects met the criteria for obesity surgery (BMI ≥40 kg/m², or ≥35 kg/m² with at least one obesity comorbidity). Subjects were weight stable (±3 kg) for at least 3 months before the surgery. Seventeen (25%) of the subjects had T2D with a fasting glycemia >7 mmol/l and/or the use of an antidiabetic drug (n = 13, 19%). Patients were exempt from antibiotic treatment 3 months prior to the intervention and during the follow-up. They only received an i.v. flash of antibiotics as part of the routine surgical protocol. They benefited from a detailed bioclinical exploration as described previously (39). Briefly, body composition was determined by dual-energy X-ray absorptiometry (DXA, Hologic). In a subset of subjects, paired biopsies of abdominal periumbilical SC and OM AT were obtained during the surgical procedure. Blood samples were taken after 12 hours of overnight fasting before the surgery and 3, 6, 12 months afterward. Clinical variables were measured as described elsewhere (39). We also collected AT biopsy samples from nonobese subjects who did not report T1D or T2D and underwent elective surgery (e.g., hernia and...
Pended into water at 4°C for 6 days. Supernatant was filtered through an 0.22 μM filter and ultra-filtrated through a 3-kDa centrifugal filter unit (Amicon-Millipore). The flow-through was then lyophilized. Fractions are expressed in arbitrary units with 1 arbitrary unit being equivalent to 25 μl of bacterial supernatant. For cytokine detection, BD Golgi Plug (BD Biosciences) was added 1 hour after the beginning of the stimulation. Anti-MR1 blocking mAb (clone 26.5, provided by Ted Hansen, Washington University School of Medicine, St. Louis, Missouri, USA) was added in some wells. The coculture experiments on PBMCs from healthy donors with AT samples from obese patients were done in RPMI medium supplemented with 10% fetal bovine serum; the AT was removed after 24 hours, and flow cytometric analysis was performed 48 hours later. In some experiments MAIT ligand (1 U/ml) was added for a further 48 hours, followed by flow cytometric analysis.


Nissen fundoplication). These were used as controls. Clinical characteristics of the patients and controls are summarized in Tables 1 and 2 and Supplemental Table 1.

**PBMC and AT preparation.** Cells of the stromal vascular fraction (SVF) were obtained by collagenase digestion of AT as previously reported (40) and were resuspended in endotoxin-free PBS supplemented with 2% FCS and 1 mM EDTA. SVF cells and freshly isolated PBMCs were stained either directly after isolation, or for detection of cytokine production after stimulation in RPMI medium supplemented with 10% fetal bovine serum (Life Technologies) with PMA and ionomycin (Sigma-Aldrich) at 25 ng/ml and 1 μg/ml, respectively, in the presence of brefeldin A at 10 μg/ml (Sigma-Aldrich) for 6 hours at 37°C. For stimulation with MAIT cell–specific ligand, HeLa cells and PBMCs from T2D patients were plated, at a final concentration of 10⁶ cells/ml each, in RPMI medium supplemented with 10% fetal bovine serum in the presence of various concentrations of MAIT ligand semi-purified bacterial fraction and incubated overnight. For ligand preparation, E. coli were cultured to the stationary phase, washed in PBS, and resuspended into water at 4°C for 6 days. Supernatant was filtered through a 0.22 μM filter and ultra-filtrated through a 3-kDa centrifugal filter unit (Amicon-Millipore). The flow-through was then lyophilized. Fractions are expressed in arbitrary units with 1 arbitrary unit being equivalent to 25 μl of bacterial supernatant. For cytokine detection, BD Golgi Plug (BD Biosciences) was added 1 hour after the beginning of the stimulation. Anti-MR1 blocking mAb (clone 26.5, provided by Ted Hansen, Washington University School of Medicine, St. Louis, Missouri, USA) was added in some wells. The coculture experiments on PBMCs from healthy donors with AT samples from obese patients were done in RPMI medium supplemented with 10% fetal bovine serum; the AT was removed after 24 hours, and flow cytometric analysis was performed 48 hours later. In some experiments MAIT ligand (1 U/ml) was added for a further 48 hours, followed by flow cytometric analysis.

Flow cytometric analysis. The following antibodies were used: anti-CD195 (2D7/CCR5), anti–IFN-γ (4S.B3), anti–IL-17a (N49-653), anti–IL-10 (JES3-19F1), anti–TNF-α (6401.1111), anti-CD25 (M-A251), anti–IL-4 (8D4-8), anti–IL-2 (MQ1-17H12), anti–CD8α (SK1), anti–CD8β (SK7), anti–CD3 (UCHT1), anti–CD45 (H12F11), anti–CD27 (M-T271), anti–CD3 (UCHT1), anti–CD45 (H12F11), anti–CD27 (M-T271), and anti–CD38 (HIT2).
CD69 (FN50), anti-GrB (GB11), anti-TCRγδ (BI), anti-IL-13 (JES10-5A2), and anti-Ki-67 (B56) from BD Biosciences; anti-CD69 (FN50), anti-Vu24J18 (6B11), anti-CD4 (OKT4), and anti-CD161 (HP-3G10) from eBioscience; anti-Vu2.2 (3C10), anti-CD4 (OKT4), anti-CD3 (OKT3), anti-CD161 (HP-3G10), anti-CCR6 (G034E3), and anti-Bel-2 (clone 100) from BioLegend; anti-CD56 (N901) and anti-CD127 (R34.34) from Beckman Coulter; and anti-CD3 (BW264/56) and anti-CD56 (AF12-7H3) from Miltenyi Biotec. In some experiments biotinylated anti-Vu2.2 (3C10) and streptavidin Qdot 605 (Life Technologies) were used. Biotinylated human MR1 tetramers loaded with the active ligand rRL-6-CH2OH (6-HM) were used to specifically identify MAIT cells; biotinylated MR1 tetramers loaded with the non-activating ligand 6-formyl-pterin (6-FP) were used as a negative control (11). MR1 tetramers were coupled to streptavidin PE (BD Biosciences). Data acquisition was performed using a BD Biosciences LSRFortessa cytometer, and results were analyzed using FlowJo analysis software (Tree Star).

Statistics. Categorical variables are expressed as numbers (n) and percentages (%). Nonparametric tests were performed using Mann-Whitney U or Wilcoxon test, as appropriate. Correlation analyses were performed using Spearman’s correlation. All P values are 2-sided, and P values less than 0.05 were considered to be statistically significant. Kinetic analyses were made using a linear mixed-effects model (for paired data). Analyses were performed using GraphPad software (GraphPad Prism) and R statistical software, version 3.0.1 (http://www.r-project.org/).

Study approval. The Ethics Committee (Comité de protection des personnes [CPP] Ile-de-France) approved the clinical investigations for both obese and nonobese individuals. All subjects provided written informed consent when included in the surgery program. The study was conducted in accordance with the Helsinki Declaration, and was registered in a public trial registry: ClinicalTrials.gov number NCT00476658.

Acknowledgments

We thank all the patients and their physicians, the nurse and technician staff (Rohia Allil) who helped with the study. We are grateful to Yannick Simon for discussion and Michael Gesnouin for technical help. We thank Antoine Soprani, INSERM, UMRS 1138, Geoffroy Saint-Hilaire Clinic, Paris, for providing human AT for in vitro cultures. We thank the Direction of Clinical Research (CRC) for support of this clinical investigation (PHRC 02076 and PHRC microbaria), as well as the Fondation pour la Recherche Médicale (FRM, no. DEQ20140329520 to A. Lehuen and DEQ20120323701 to K. Clément), the National Agency of Research (ANR Fibrota and ObeMAIT projects), the French national program “Investissements d’Avenir” with the reference ANR-10-IAHU-05, the LabEx INFLAMEX with the reference ANR-11-IDEX-0005-02, and Département Hospitalo-Universitaire (DHU) AutHors (Autoimmune and Hormonal Diseases).

Address correspondence to: Agnès Lehuen, Institut Cochin, INSERM U1016, CNRS UMR8104, 123 Boulevard Port-Royal, 75014 Paris, France. Phone: 331.76.53.55.90; Fax: 331.46.34.64.54; E-mail: agnes.lehuen@inserm.fr.


